Ascidian Therapeutics
Latest round
- Series A
Last raised
- Nov 2023
Total raised
- $90M
Investors
- 1
About Ascidian Therapeutics
Based in Boston, US, and founded in 2020, Ascidian Therapeutics, created by ATP, is a biotech company that employs technologies to enable the therapeutic targeting of genes and genes with mutational diversity while preserving native gene expression patterns and levels to provide durability to gene therapy. In November 2023, Ascidian Therapeutics, Inc. The firm offers an RNA exon editing platform to create a novel RNA exon editor that offers a single exon editing molecule that can be used to replace several mutant exons via pre-mRNA trans-splicing, without changing DNA or introducing foreign enzymes to help reduce the risks associated with DNA editing and manipulation and has applications in ophthalmology, neurological and neuromuscular disorders, and other rare diseases.
Who invested in Ascidian Therapeutics
1 investor across 2 rounds
See all investors in Ascidian Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ascidian Therapeutics
Who invested in Ascidian Therapeutics?
Ascidian Therapeutics has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ascidian Therapeutics raised?
Ascidian Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ascidian Therapeutics last raise money?
Ascidian Therapeutics's most recent round on record is a Series A, in Nov 2023.
What does Ascidian Therapeutics do?
Based in Boston, US, and founded in 2020, Ascidian Therapeutics, created by ATP, is a biotech company that employs technologies to enable the therapeutic targeting of genes and genes with mutational diversity while preserving native gene expression patterns and levels to provide durability to gene therapy.
Where is Ascidian Therapeutics headquartered?
Ascidian Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Ascidian Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ascidian Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ascidian Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.